Literature DB >> 23820062

Implication of minimal extrathyroidal extension as a prognostic factor in papillary thyroid carcinoma.

Jae Ho Shin1, Tae Kwun Ha, Ha Kyoung Park, Min Sung Ahn, Kwang Hee Kim, Ki Beom Bae, Tae Hyeon Kim, Chang Soo Choi, Tae Kyoon Kim, Sung Kwon Bae, Sang Hyo Kim.   

Abstract

PURPOSE: Extrathyroidal extension (ETE) of papillary thyroid carcinoma (PTC) is a risk factor for tumor recurrence. By TNM Classification (7th edition), differentiated thyroid carcinoma with ETE is designated T3 (minimal invasion), T4a (extended invasion), or T4b (more extensive unresectable invasion), according to the degree of tumor involvement. We subsequently focused our investigation on minimal ETE (MEE), analyzing the clinicopathologic characteristics, recurrence rate, and recurrence-free survival (RFS) in this setting.
METHODS: A retrospective study was conducted, based on 332 patients undergoing thyroidectomy for PTC between January 2005 and December 2006.
RESULTS: The study population was stratified into two groups: PTC with MEE (103/332; 31.0%) and PTC without MEE (229/332; 69.0%). In patients with PTC, MEE correlated with gender, tumor size, multifocality, lymph node (LN) metastasis, underlying Hashimoto's thyroiditis, and the nature of the surgery. However, no significant intergroup differences were evident with respect to age, recurrence rate, and LN metastasis. In multivariate analysis, LN metastasis (odds ratio = 2.273; 95% confidence interval, 1.280-4.037) was recognized as an independent correlate of mETE (p = 0.005). However, recurrence-free survival did not differ significantly between the groups (p = 0.153), even when further stratified by the presence or absence of LN metastasis.
CONCLUSION: In patients with PTC, MEE does not impact RFS. Thus, appropriate surgical intervention and postoperative follow up are mandatory in PTC, regardless of its extent.
Copyright © 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Minimal extrathyroidal extension; Papillary thyroid carcinoma; Recurrence; Recurrence-free survival

Mesh:

Year:  2013        PMID: 23820062     DOI: 10.1016/j.ijsu.2013.06.015

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  27 in total

Review 1.  Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

Authors:  B Xu; R Ghossein
Journal:  Eur J Surg Oncol       Date:  2017-05-18       Impact factor: 4.424

2.  Intraoperative frozen section for the evaluation of extrathyroidal extension in papillary thyroid cancer.

Authors:  Young Min Park; Soo-Geun Wang; Jin Young Goh; Dong Hoon Shin; In-Ju Kim; Byung-Joo Lee
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

Review 3.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

4.  Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases.

Authors:  Fabián Pitoia; Erika Abelleira; Graciela Cross
Journal:  Eur Thyroid J       Date:  2014-12-06

Review 5.  Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

6.  Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.

Authors:  Nathalie Chereau; Etienne Dauzier; Gaëlle Godiris-Petit; Séverine Noullet; Isabelle Brocheriou; Laurence Leenhardt; Camille Buffet; Fabrice Menegaux
Journal:  Langenbecks Arch Surg       Date:  2018-02-14       Impact factor: 3.445

Review 7.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Nancy D Perrier; James D Brierley; R Michael Tuttle
Journal:  CA Cancer J Clin       Date:  2017-11-01       Impact factor: 508.702

8.  Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma.

Authors:  Henry K Su; Bruce M Wenig; Grace C Haser; Meghan E Rowe; Sylvia L Asa; Zubair Baloch; Eugenie Du; William C Faquin; Giovanni Fellegara; Thomas Giordano; Ronald Ghossein; Virginia A LiVolsi; Ricardo Lloyd; Ozgur Mete; Umut Ozbek; Juan Rosai; Saul Suster; Lester D Thompson; Andrew T Turk; Mark L Urken
Journal:  Thyroid       Date:  2016-04       Impact factor: 6.568

9.  Papillary thyroid carcinoma: different clinical behavior among pT3 tumors.

Authors:  Maria Joana Santos; Maria João Bugalho
Journal:  Endocrine       Date:  2016-03-21       Impact factor: 3.633

10.  Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.

Authors:  Wei Sun; Xiabin Lan; Zhihong Wang; Wenwu Dong; Liang He; Ting Zhang; Hao Zhang
Journal:  Med Oncol       Date:  2016-08-10       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.